Standard Biotools Inc (LAB)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $279.27M
Last updated: Nov 17, 2026 at 4:32 PM ET
Standard Biotools Inc (LAB) Statistics
Standard Biotools (LAB) has a market cap of $279.27M and an enterprise value of $12.09M. It kept 208.40% of revenue as net income over the last 12 months. It holds $267.19M more cash than debt, 95.67% of its market cap.
Total Valuation
Enterprise value is 95.67% below the market cap, as cash exceeds debt.
| Market Cap | $279.27M |
|---|---|
| Enterprise Value | $12.09M |
| Latest price (Nov 17, 2026) | $0.54 |
Key Dates
| Last Earnings Date | Nov 3, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.3x and 0.4x. Its year-end P/S ranged from 0.9x to 7.5x from 2022 to 2025.
| P/S Ratio | 3.3x |
|---|---|
| P/B Ratio | 0.4x |
Price Statistics
The stock is down 56.50% over 52 weeks and trades 19.40% below its 50-day average.
| Beta (1Y) | 1.17 |
|---|---|
| 52-Week Change | -56.50% |
| 1-Month Change | -16.15% |
| 3-Month Change | -19.68% |
| 6-Month Change | -46.06% |
| Total Return (1Y) | -56.50% |
| Total Return (3Y CAGR) | -37.78% |
| Max Drawdown (1Y) | -67.89% |
| Max Drawdown (3Y) | -81.53% |
| Sharpe Ratio (1Y) | -1.15 |
| Correlation with SPY (1Y) | 0.22 |
| 50-Day Average | $0.67 |
| 200-Day Average | $0.86 |
| 52-Week Range | $0.59 to $1.72 |
| RSI (14 Days) | 35.8 |
| Average Volume (20 Days) | 1.03M |
Financial Position
Current assets cover 9.75x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 9.75x |
|---|---|
| Quick Ratio | 9.40x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on invested capital is -9.94% over the last 12 months, against a 5-year average of 293.38%.
| Return on Equity (ROE) | 23.95% |
|---|---|
| Return on Assets (ROA) | 20.95% |
| Return on Invested Capital (ROIC) | -9.94% |
| ROA (5Y Average) | -25.84% |
| ROIC (5Y Average) | 293.38% |
| Asset Turnover | 0.11x |
| Inventory Turnover | 1.64x |
| Receivables Turnover | 4.45x |
| Cash Conversion Cycle | 221 days |
Scores
LAB has an Altman Z-Score of -0.42, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.42 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $63.86M over the last 12 months is up 2.29% from the 12 months before.
| Revenue | $63.86M |
|---|---|
| Revenue Growth (YoY) | +2.29% |
| Gross Profit | $35.36M |
| Operating Income | -$76.30M |
| Pretax Income | -$70.34M |
| Net Income | $133.08M |
| Reported EPS (TTM) | -$0.06 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 87.47% of the $635.33M in total assets.
| Cash and Equivalents | $267.49M |
|---|---|
| Total Debt | $300.00K |
| Net Cash | $267.19M |
| Net Cash Per Share | $0.68 |
| Working Capital | $446.28M |
| Shareholder Equity | $555.75M |
| Book Value Per Share | $1.41 |
| Total Assets | $635.33M |
| Total Liabilities | $79.58M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$64.26M |
|---|---|
| FCF Per Share | -$0.17 |
| Depreciation and Amortization | $8.68M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -119.48%.
| Gross Margin | 55.38% |
|---|---|
| Operating Margin | -119.48% |
| Pretax Margin | -110.15% |
| Net Margin | 208.40% |
| Gross Margin (5Y Average) | 47.51% |
Growth
Revenue fell 4.49% a year over 3 years.
| Revenue Growth (3Y CAGR) | -4.49% |
|---|---|
| Revenue Growth (5Y CAGR) | -9.19% |
Dividends and Yields
LAB does not pay a dividend.
| Buyback Yield | -0.16% |
|---|---|
| Shareholder Yield | -0.16% |
Peer Position
Against 12 similar companies, LAB has the 5th highest P/S.
P/S RatioPeer median 2.3x
ROICPeer median -26.15%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +13.78%
| P/S Ratio | 3.3x vs 2.3x median |
|---|---|
| ROIC | -9.94% vs -26.15% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +2.29% vs +13.78% median |
Analyst Forecast
Consensus estimates put revenue growth at -1.91% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -1.91% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About LAB
What is LAB's market cap?
Standard Biotools has a market cap of $279.27M. Its enterprise value, which adds debt and subtracts cash, is $12.09M.
How many shares of LAB are outstanding?
Standard Biotools has 393.56M shares outstanding. The count is up 2.86% from a year earlier.
Does LAB pay a dividend?
No. Standard Biotools does not pay a dividend.
How much debt does LAB have?
Standard Biotools has $300.00K of total debt and $267.49M of cash and equivalents, a net cash position of $267.19M.
LAB pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts